Terumo Pharmaceutical Solutions Division ads

K-Pack Embrace™ reduces the risk of needle stick injuries with its integrated hinged needle shield, which can be activated with one hand and provides audible, visual and tactile confirmation of engagement. For more information about the K-Pack Embrace™ active safety needle, read the full release. 👇

Co-packing a pre-selected injection needle with a drug product and syringe can significantly reduce the risks to the patient, add convenience for the healthcare professional (HCP) and simultaneously maintain the value proposition of the product for the drug company. The K-Pack Embrace™ active safety needle is designed specifically for automated co-packing processes with its compact hard-shell case. For more information about the K-Pack Embrace™ active safety needle, read the full release. 👇

The K-Pack Embrace™ active safety needle is designed specifically for automated co-packing processes with its compact hard-shell case. It is intended for subcutaneous (SC), intramuscular (IM) and intravenous (IV) applications and includes Terumo’s T-Sharp™ technology with integrated needle shield safety features. For more information about the K-Pack Embrace™ active safety needle, read the full release. 👇

Terumo Corporation today announced the global commercial launch of its K-Pack Embrace™ active safety needle. The new safety injection needle is packaged in a rigid cap and case container, designed to facilitate the downstream co-packing processes and protect the needle through the product life cycle until the point of use. For more information about the K-Pack Embrace™ active safety needle, read the full release. 👇

𝗢𝘂𝗿 𝗡𝗲𝘄 𝗪𝗲𝗯𝘀𝗶𝘁𝗲 𝗶𝘀 𝗟𝗶𝘃𝗲: 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗖𝗗𝗠𝗢 𝗖𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 𝗳𝗼𝗿 𝗣𝗮𝗿𝗲𝗻𝘁𝗲𝗿𝗮𝗹 𝗗𝗿𝘂𝗴𝘀 The new Terumo Pharmaceutical Solutions Division website is now live, showcasing our integrated CDMO capabilities for parenteral drug development and manufacturing. From initial combination device design and formulation development through to commercial manufacturing, we support every stage of the journey with specialised expertise and advanced sterile injectable solutions, helping to deliver better patient outcomes worldwide. Our CDMO offering brings together device engineering, formulation development, and aseptic manufacturing capabilities, designed to help accelerate development, streamline scale-up, and support successful global launches. Explore our CDMO capabilities on the new website and discover how we can support your next project: https://lnkd.in/eZGiDZHj #TerumoPharmaceuticalSolutionsDivision #CDMO #ParenteralDrugs #NewWebsite

Noritsugu Fujita, Division President, Pharmaceutical Solutions Division, will be in New York from March 23–26 for DCAT. If you’re attending DCAT, book a meeting to connect and explore how Terumo Pharmaceutical Solutions’ amplified global reach can support your parenteral programs worldwide. We look forward to discussing how our global network and integrated capabilities can help advance your next project. 📩 Book a meeting with Fujita and the Terumo Pharmaceutical Solutions team by emailing [email protected] #TerumoPharmaceuticalSolutions #DCAT2026 #NewYork #GlobalPharma #Meetings